Company Profile

Syros is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies. Driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, Syros is focused on advancing a late-stage clinical pipeline, including tamibarotene, an oral selective RARĪ± agonist in patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia with RARA gene overexpression, and SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia. Syros is seeking partnerships for SY-5609, a highly selective and potent CDK7 inhibitor in clinical development for the treatment of select solid tumors, and multiple preclinical programs in oncology.

Contact Information

Investor Relations
Syros Pharmaceuticals
Karen Hunady
Director of Corporate Communications & Investor Relations
khunady@syros.com

Stern Investor Relations, Inc.
Hannah Deresiewicz
hannahd@sternir.com

Company Contact
Syros Pharmaceuticals, Inc.
35 CambridgePark Drive
Cambridge, MA 02140